Document Detail

Biological response modifiers.
MedLine Citation:
PMID:  6188871     Owner:  NLM     Status:  MEDLINE    
It is clear that the rate of change in biology is rapidly accelerating. This is most apparent in the BRM area with respect to the development of new cancer therapies. New surgical approaches are being developed, and new forms of delivery for therapeutic radiation are now available. Radiosensitizers are now also being tested. Similarly, new chemotherapeutic agents and new methods of utilizing existing drugs are being developed. However, the use of BRM either alone or in combination with these other modalities is the area of greatest change and can be expected to be a major factor in achieving a greater understanding of cancer biology and a greater therapeutic specificity in the treatment of cancer patients in this decade (2, 65). Given the new technology of the 1980's, this is an exciting time. It is hoped that sufficient resources will be available to support continuing efforts to develop biologicals into effective anticancer agents. The rapidly advancing technologies of computers, cell fusion, and genetic engineering are all interrelated through the underpinnings of molecular biology to offer us unparalleled opportunities in biological research. These opportunities should translate into more effective treatments for cancer in this decade.
R K Oldham
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of the National Cancer Institute     Volume:  70     ISSN:  0027-8874     ISO Abbreviation:  J. Natl. Cancer Inst.     Publication Date:  1983 May 
Date Detail:
Created Date:  1983-06-23     Completed Date:  1983-06-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7503089     Medline TA:  J Natl Cancer Inst     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  789-96     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use
Antibodies, Monoclonal / immunology
Antigens, Neoplasm / immunology
Biological Products / therapeutic use
Clinical Trials as Topic
Drug Evaluation, Preclinical
Immunosuppressive Agents / therapeutic use
Interferon Inducers / therapeutic use
Interferons / therapeutic use
Lymphokines / therapeutic use
Neoplasms / immunology,  therapy*
Neoplasms, Experimental / therapy
T-Lymphocytes / immunology
Thymus Extracts / therapeutic use
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Antibodies, Monoclonal; 0/Antigens, Neoplasm; 0/Biological Products; 0/Cytokines; 0/Immunosuppressive Agents; 0/Interferon Inducers; 0/Lymphokines; 0/Thymus Extracts; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biochemical and electron microscopic observations of cytotoxic effect of a fraction from hemolytic s...
Next Document:  Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glan...